CLARITIN-D 24 HOUR Drug Patent Profile

When do Claritin-d 24 Hour patents expire, and what generic alternatives are available?

Claritin-d 24 Hour is a drug marketed by Bayer Healthcare Llc and is included in one NDA.

The generic ingredient in CLARITIN-D 24 HOUR is loratadine; pseudoephedrine sulfate. There are thirty-nine drug master file entries for this compound. Thirty-one suppliers are listed for this compound. Additional details are available on the loratadine; pseudoephedrine sulfate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Claritin-d 24 Hour

A generic version of CLARITIN-D 24 HOUR was approved as loratadine; pseudoephedrine sulfate by PERRIGO PHARMA INTL on January 30^th, 2003.

Summary for CLARITIN-D 24 HOUR

US Patents:	0
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	2
Clinical Trials:	27
Patent Applications:	2
DailyMed Link:	CLARITIN-D 24 HOUR at DailyMed

Recent Clinical Trials for CLARITIN-D 24 HOUR

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Andover Research Eye Institute	Phase 4
National Cancer Institute (NCI)	Early Phase 1
Rutgers, The State University of New Jersey	Early Phase 1

See all CLARITIN-D 24 HOUR clinical trials

Pharmacology for CLARITIN-D 24 HOUR

Drug Class	alpha-Adrenergic Agonist
Mechanism of Action	Adrenergic alpha-Agonists

US Patents and Regulatory Information for CLARITIN-D 24 HOUR

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Bayer Healthcare Llc	CLARITIN-D 24 HOUR	loratadine; pseudoephedrine sulfate	TABLET, EXTENDED RELEASE;ORAL	020470-002	Nov 27, 2002		OTC	Yes	Yes

Expired US Patents for CLARITIN-D 24 HOUR

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Bayer Healthcare Llc	CLARITIN-D 24 HOUR	loratadine; pseudoephedrine sulfate	TABLET, EXTENDED RELEASE;ORAL	020470-002	Nov 27, 2002	4,659,716*PED
Bayer Healthcare Llc	CLARITIN-D 24 HOUR	loratadine; pseudoephedrine sulfate	TABLET, EXTENDED RELEASE;ORAL	020470-002	Nov 27, 2002	5,314,697*PED
Bayer Healthcare Llc	CLARITIN-D 24 HOUR	loratadine; pseudoephedrine sulfate	TABLET, EXTENDED RELEASE;ORAL	020470-002	Nov 27, 2002	4,863,931*PED

International Patents for CLARITIN-D 24 HOUR

See the table below for patents covering CLARITIN-D 24 HOUR around the world.

Country	Patent Number	Title	Estimated Expiration
Germany	69316023
Israel	107354	FILM-COATED EXTENDED RELEASE ORAL DOSAGE COMPOSITION
Australia	4337289
Luxembourg	90738
Finland	90977

Supplementary Protection Certificates for CLARITIN-D 24 HOUR

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0152897	2001C/013	Belgium		PRODUCT NAME: DESLORATADINE; REGISTRTION NO/DATE: EU/1/00/160/010 20010115
1110543	08C0004	France		PRODUCT NAME: DESLORATADINE; PSEUDOEPHEDRINE SULFATE; REGISTRATION NO/DATE: EU/1/07/399/001 20070730
0152897	SPC/GB01/012	United Kingdom		PRODUCT NAME: DESLORATADINE AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF; REGISTERED: UK EU/1/00/157/001-013 20010115; UK EU/1/00/158/001-013 20010115; UK EU/1/00/159/001-013 20010115; UK EU/1/00/160/001-013 20010115; UK EU/1/00/161/001-013 20010115
0152897	C00152897/01	Switzerland		FORMER REPRESENTANTIVE: E. BLUM AND CO. PATENTANWAELTE, CH

CLARITIN-D 24 HOUR Market Analysis and Financial Projection Experimental

Market Dynamics and Financial Trajectory for Claritin-D 24 Hour

Market Overview

Claritin-D 24 Hour, a popular antihistamine and decongestant combination, is a significant player in the global allergy medication market. Here’s a detailed look at its market dynamics and financial trajectory.

Market Size and Growth

The Claritin market, which includes Claritin-D 24 Hour, was valued at USD 0.16 billion in 2023 and is projected to reach USD 0.26 billion by 2031, growing at a CAGR of 5.67% during the forecast period of 2024-2031[1].

Global Market Drivers

Several factors drive the growth of the Claritin-D 24 Hour market:

Product Innovation

Continuous research and development have led to novel formulations, including extended-release variants and combination medicines. These innovations enhance convenience and efficacy, appealing to consumers seeking better allergy relief[1].

Alterations in Lifestyle Factors

Urbanization and increased exposure to allergens such as pollen, dust mites, and pet dander have resulted in a higher demand for allergy treatments. This shift in lifestyle factors contributes significantly to the market growth[1].

Seasonal Demand

Seasonal allergies, particularly during spring and autumn, increase the demand for allergy relief medicines like Claritin-D 24 Hour. This seasonal variability is a key driver of the market[1].

Promotions and Marketing

Effective marketing strategies, including commercials and promotions, enhance brand awareness and stimulate sales. Strong marketing efforts are crucial for the market's expansion[1].

Global Expansion

The expansion of Claritin-D 24 Hour into new markets and regions increases its consumer base and potential revenue. This global outreach is vital for sustained growth[1].

Market Restraints

Despite the growth drivers, several factors act as restraints to the Claritin-D 24 Hour market:

Competition from Generic Brands

The presence of generic loratadine products at lower prices can constrain the market share of branded Claritin-D 24 Hour, impacting profitability[1].

Market Saturation

The presence of numerous established antihistamine medicines can lead to market saturation, complicating Claritin-D 24 Hour’s efforts to sustain growth[1].

Adverse Effects and Consumer Reservations

Some consumers may be reluctant to use antihistamines due to potential side effects, although Claritin-D 24 Hour is non-drowsy. This consumer skepticism can hinder widespread acceptance[1].

Regulatory Challenges

Changes in legislation or constraints on advertising and marketing can influence the promotion and sale of Claritin-D 24 Hour[1].

Economic Factors

Economic recessions or fluctuations can impact consumer expenditure on healthcare products, including allergy medications[1].

Changes in Consumer Preferences

Increasing trends towards natural and holistic health treatments may prompt customers to seek alternatives to traditional drugs like Claritin-D 24 Hour[1].

Segmentation Analysis

The global Claritin market, including Claritin-D 24 Hour, is segmented based on several criteria:

Product Type

The market includes various formulations such as tablets, capsules, and syrups. Tablets, in particular, dominate the market with a significant share[4].

Distribution Channel

Online retail has emerged as a dynamic sub-segment, experiencing significant growth due to increasing digital penetration and the convenience of home delivery. Health stores also play a crucial role, catering to health-conscious consumers[1].

Geography

The market is segmented into North America, Europe, Asia-Pacific, Latin America, and the Middle East and Africa. North America, particularly the United States and Canada, has significant market penetration due to strong brand recognition and high prevalence of allergic conditions[1].

Efficacy and Clinical Benefits

Claritin-D 24 Hour is known for its rapid onset of action and comprehensive relief:

Rapid Onset of Action

Claritin-D 24 Hour starts to work in as little as 30 minutes, providing significant relief for patients with allergic rhinitis and nasal congestion[2].

Clinical Studies

In clinical trials, Claritin-D 24 Hour has shown to provide greater relief of nasal congestion and runny nose compared to placebo. It also improves nasal airflow more effectively than other treatments like Flonase[2].

Key Players

The major players in the Claritin market include:

• Bayer AG
• Sanofi
• Pfizer
• Johnson & Johnson
• Merck

These companies play a significant role in the development, marketing, and distribution of Claritin-D 24 Hour[1].

Financial Trajectory

The financial trajectory of Claritin-D 24 Hour is closely tied to the overall growth of the Claritin market:

Revenue Projections

The Claritin market is expected to grow from USD 0.16 billion in 2023 to USD 0.26 billion by 2031, indicating a steady increase in revenue[1].

Market Share

The market share of Claritin-D 24 Hour is influenced by its strong brand recognition, effective marketing, and the growing demand for allergy treatments. North America, particularly, contributes significantly to its revenue due to high consumer trust and prevalence of allergic conditions[1].

Geographical Performance

The geographical performance of Claritin-D 24 Hour varies across different regions:

North America

This region has the highest market penetration due to strong brand recognition and a high prevalence of allergic conditions. The United States and Canada are key markets[1].

Europe

Countries like Germany and the UK show substantial demand, influenced by rising pollen levels and increased awareness about allergic rhinitis[1].

Asia-Pacific

This region is emerging as a significant market driven by a growing population, urbanization, and higher disposable income, contributing to increased healthcare spending and awareness of allergy-related products[1].

Consumer Preferences and Trends

Consumer preferences play a crucial role in the market dynamics of Claritin-D 24 Hour:

Preference for Convenience

Consumers increasingly prefer once-daily treatments and oral tablets over sprays, which aligns with the product offerings of Claritin-D 24 Hour[2].

Awareness of Drug Interactions

As consumers become more aware of potential drug interactions, they may prefer products like Claritin-D 24 Hour that offer comprehensive relief without significant side effects[1].

Key Takeaways

• Market Growth: The Claritin market, including Claritin-D 24 Hour, is projected to grow at a CAGR of 5.67% from 2024 to 2031.
• Drivers: Product innovation, lifestyle changes, seasonal demand, effective marketing, and global expansion drive the market.
• Restraints: Competition from generics, market saturation, adverse effects, regulatory challenges, economic factors, and changes in consumer preferences act as restraints.
• Efficacy: Claritin-D 24 Hour offers rapid onset of action and comprehensive relief for allergic rhinitis and nasal congestion.
• Geographical Performance: North America, Europe, and the Asia-Pacific region are key markets with varying growth dynamics.

FAQs

1. What is the projected market size of Claritin by 2031?

The Claritin market is projected to reach USD 0.26 billion by 2031[1].

2. What are the key drivers of the Claritin-D 24 Hour market?

Key drivers include product innovation, alterations in lifestyle factors, seasonal demand, effective marketing, and global expansion[1].

3. How quickly does Claritin-D 24 Hour start to work?

Claritin-D 24 Hour starts to work in as little as 30 minutes[2].

4. Which regions are the most significant for the Claritin-D 24 Hour market?

North America, Europe, and the Asia-Pacific region are the most significant markets for Claritin-D 24 Hour[1].

5. What are the main restraints to the growth of the Claritin-D 24 Hour market?

Main restraints include competition from generic brands, market saturation, adverse effects, regulatory challenges, economic factors, and changes in consumer preferences[1].

Cited Sources:

1. Verified Market Research: Claritin Market Size, Share, Growth, Trends & Forecast.
2. Claritin: Claritin-D® Efficacy.
3. Perrigo Investor Relations: Andrx and Perrigo Announce Agreement to Market Loratadine Products.
4. The Brainy Insights: Loratadine Market Size, Share, Growth & Trends Report, 2033.
5. Claritin: Claritin-D® Tablets 24-Hour.